07th week of 2011 patent applcation highlights part 33 |
Patent application number | Title | Published |
20110039734 | siRNA targeting connective tissue growth factor (CTGF) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to CTGF. | 2011-02-17 |
20110039735 | PROBE DESIGN FOR OLIGONUCLEOTIDE FLUORESCENCE IN SITU HYBRIDIZATION (FISH) - A method and a system for selecting a set of FISH probe oligonucleotide sequences from a plurality of overlapping tiled candidate FISH probe oligonucleotide sequences are provided. A composition that includes FISH probes with sequences from the set of FISH probe oligonucleotide sequences is also provided. | 2011-02-17 |
20110039736 | METHOD OF IMMOBILIZING BIOLOGICALLY ACTIVE SUBSTANCE - An object of the present invention is to provide a method of immobilizing the biologically active substance which has an excellent capability of immobilizing a target biologically active substance, and exhibits low nonspecific adsorption of the biologically active substance to provide a high S/N ratio, without using a functional group for fixing the biologically active substance and without having a process of inactivating the functional group for fixing the biologically active substance after immobilizing the biologically active substance. The above object is achieved by a method of immobilizing a biologically active substance comprising the step of: bringing a solution into contact with a compound-side surface of an immobilizing substrate to immobilize the biologically active substance on a surface of the immobilizing substrate, the solution being prepared by dissolving the biologically active substance in a phosphate buffer having a phosphate concentration of 0.1 M or more, and the immobilizing substrate comprising a substrate and a compound containing a hydrophilic group inhibiting nonspecific adsorption on a surface of the substrate. | 2011-02-17 |
20110039737 | BINDERS FOR BINDING BEDS AND LOOSE FORMATIONS AND PROCESSES FOR PRODUCING THEM - A binder is described which comprises A) a hydrolysate or heterocondensate of at least one hydrolysable silicon compound and at least one metal, phosphorus or boron compound, the metal being selected from Al, Ge, Sn, Pb, Ti, Mg, Li, V, Nb, Ta, Zr and Hf, B) an organic polymerizable or polycondensable monomer or oligomer and C) a buffer, so that the pH of the buffered binder is in the range from 2 to 7, and optionally a complexing agent, if appropriate, the at least one hydrolysable silicon compound comprising one or more hydrolysable silicon compounds having at least one nonhydrolysable group or oligomers thereof. The binder is suitable for consolidating bulk or loose substrates. | 2011-02-17 |
20110039738 | Thermally Conductive Silicone Grease Composition - A thermally conductive silicone grease composition comprising at least the following components: an organopolysiloxane (A) represented by the following general formula: [wherein R | 2011-02-17 |
20110039739 | POLYALKYLENE GLYCOL-BASED WIND TURBINE LUBRICANT COMPOSITIONS - A lubricant composition that is especially useful under extreme conditions, such as in wind turbine gearboxes, comprises a mixed feed glycol; a polyol ester; two particular antioxidants; a phosphorus-based extreme pressure additive; a yellow metal passivator; and at least one specified corrosion inhibitor. The composition passes testing according to ASTM D665B even at 168 hours from initiation, and/or the SKF-Emcor Test Method DIN 51802:1990. | 2011-02-17 |
20110039740 | ENGINE LUBRICANTS - An engine lubricant, especially an SAE OW engine lubricant is described. The engine lubricant has at least 15 wt % of at least one monoester and not more than 15 wt % of additives, wherein said at least one monoester, or mixture of said monoesters if more than one is present, has a kinematic viscosity at 100° C. of not more than 3.3, a viscosity index of at least 130 and a Noack evaporation loss of not more than 15 wt %. The monoester is preferably the reaction product of a monohydric alcohol and a monocarboxylic acid wherein said monohydric alcohol is at least one saturated branched-chain aliphatic monohydric alcohol having between 16 and 36, carbon atoms and wherein said monocarboxylic acid is at least one saturated straight-chain aliphatic monocarboxylic acid having between 5 and 10, preferably 5 and 7, carbon atoms. In preferred lubricants, the monoester, or mixtures of monoesters, have a pour point of not more than −30° C. and a non-polarity index of at least 80. | 2011-02-17 |
20110039741 | POLYALKYLENE GLYCOL LUBRICANT COMPOSITION - A lubricant composition useful for automotive engines, comprising: (A) at least one polyalkylene glycol suitable for use as a lubricant in an automotive engine, (B) an additive package which comprises an acid scavenger, wherein the acid scavenger is an aspartic acid ester, aspartic acid amide, a Group V aspartic acid salt, or a combination thereof. | 2011-02-17 |
20110039742 | Lubricant Additives - Processes are described for producing liquid, biobased lubricant additives containing from 50 to 100% biobased carbon according to ASTM D6866 from heat-bodied oils by transesterification with biobased or petroleum based alcohols and by hydrogenation of at least the resulting diesters, triesters and polyesters. | 2011-02-17 |
20110039743 | LOW VISCOSITY OLIGOMER OIL PRODUCT , PROCESS AND COMPOSITION - The present invention relates to a low viscosity lubricant process, product, and composition characterized by low Noack volatility, low pour point, useful low temperature viscometrics, and high viscosity index and more particularly concerns a PAO composition having a kinetic viscosity at 100° C. in the range of about 4 cSt. | 2011-02-17 |
20110039744 | Personal Cleansing Compositions Comprising A Bacterial Cellulose Network And Cationic Polymer - A personal cleansing composition comprising a liquid matrix comprising water; a lathering surfactant; and an external structurant comprising a bacterial cellulose network and a cationic polymer; wherein a particulate material is suspended within the liquid matrix and the composition has a compositional pH of less than about 7. Methods of use and making are also provided. | 2011-02-17 |
20110039745 | CONCENTRATED LIQUID SOAP FORMULATIONS HAVING READILY PUMPABLE VISCOSITY - The present invention provides concentrated soap compositions formulated in such a manner that, quite unpredictably, despite high concentration of soap, they have viscosity which allows them to be pumped from, for example, consumer packaging (e.g., bottles) and/or transit or storage points during manufacture (e.g., pipes, storage tanks, etc.). | 2011-02-17 |
20110039746 | CONCENTRATED LIQUID SOAP FORMULATIONS WITH GREATER THAN 50% LONG CHAIN SOAP AND FATTY ACID HAVING READILY PUMPABLE VISCOSITY - The present invention provided concentrated soap compositions, particularly those where long chain (>C | 2011-02-17 |
20110039747 | COMPOSITION AND METHOD FOR REMOVING ION-IMPLANTED PHOTORESIST - A method and mineral acid-containing compositions for removing bulk and/or hardened photoresist material from microelectronic devices have been developed. The mineral acid-containing composition includes at least one mineral acid, at least one sulfur-containing oxidizing agent, and optionally at least one metal ion-containing catalyst. The mineral acid-containing compositions effectively remove the hardened photoresist material while not damaging the underlying silicon-containing layer(s). | 2011-02-17 |
20110039748 | Hob Cleaning Composition - Hard surface cleaning composition particularly suited for the cleaning of kitchen or cooking stove having a cooktop which includes a glass plate which is effective in the cleaning treatment of stained glass plates, and which is especially effective in the treatment of dried or baked on milk stains. | 2011-02-17 |
20110039749 | Methods for cleaning recyclable substrates or containers - A method for treating a contaminated substrate comprising the steps of contacting an emulsion to a substrate surface soiled with one or more contaminants, the emulsion comprising a blend of dibasic esters, whereby the emulsion is capable of emulsifying all or some of the contaminants, forming a resulting emulsion; removing substantially all of the resulting emulsion from the substrate surface; and, optionally, in recovering the contaminant, adding an amount of water or a solvent to the resulting emulsion effective to form at least a first phase layer comprising a substantial amount of the contaminant and a second phase layer comprising a substantial amount of the emulsion. The dibasic esters can be a blend of adipic, glutaric, and succinic diacids, and, in one particular embodiment, the blend comprises dialkyl methylglutarate and dialkyl ethylsuccinate, wherein the alkyl groups individually comprise a C | 2011-02-17 |
20110039750 | GLASSWARE CORROSION INHIBITOR - Article for use in a dishwashing machine, which comprises a water-soluble glass or ceramic composition effective to reduce corrosion of glassware and at least one surfactant containing composition, wherein the amount of the glass or ceramic composition is within the range of 5 to 95 wt. % and the amount of the surfactant is in the range of 5 to 95 wt. %, both percentages based on the weight of the article. | 2011-02-17 |
20110039751 | CLEANING AND/OR TREATMENT COMPOSITIONS - This invention relates to compositions comprising certain cellobiose dehydrogenase enzymes and processes for making and using such compositions, including the use of such compositions to clean and/or treat a situs. | 2011-02-17 |
20110039752 | Stabilized Liquid Enzyme Compositions - Peptide aldehydes or ketone derivatives are particularly efficient for stabilizing subtilisin-type proteases in aqueous compositions such as liquid detergents, including peptide compounds with OH-substituted phenylalanine aldehyde as the C-terminal residue. | 2011-02-17 |
20110039753 | Fabric Care Emulsion - The invention relates to oil-in-water emulsions, methods of making said emulsions and their uses in fabric care or hair care compositions. The fabric care composition comprises a silicone oil-in-water emulsion which emulsion is obtained by a. forming an oil phase by mixing at least one silicone compound with at least one silicone-free oil, b. optionally adding an emulsifier, c. adding water, d. forming an oil-in-water emulsion. A silicone oil, comprising a siloxane or polysiloxane compound, for example polydimethyl siloxane (polydimethyl silicone or PDMS), or a derivative thereof, e.g., amino and amido silicone, diluted with a silicone-free oil still can provide an emulsion providing high fabric care properties while decreasing the costs. | 2011-02-17 |
20110039754 | Aqueous Highly Acidic Hard Surface Cleaning Compositions - Provided are highly aqueous liquid acidic hard surface cleaning composition having a pH of about 3 or less which comprise: an acid constituent, preferably comprising sulfamic acid and preferably at least one or more further co-acids, and preferably wherein the acid constituent comprises both sulfamic acid and formic acid; at least one nonionic surfactant based on monobranched alkoxylated C10/C11-fatty alcohols; an organic solvent constituent which comprises at least one glycol ether solvent, preferably a glycol ether solvent which desirably mitigates or masks malodors of the acid constituent, especially when the acid constituent comprises formic acid; optionally a cosurfactant constituent, including one or more nonionic, cationic, amphoteric or zwitterionic surfactants; optionally one or more further constituents selected coloring agents, fragrances and fragrance solubilizers, viscosity modifying agents including one or more thickeners, pH adjusting agents and pH buffers including organic and inorganic salts, optical brighteners, opacifying agents, hydrotropes, abrasives, and preservatives, as well as other optional constituents known to the art; and the balance, water, wherein water comprises at least 80% wt. of the composition. | 2011-02-17 |
20110039755 | Fragrance - A method of providing to a fragrance application a musky odour, comprising the addition thereto of at least one compound according to the formula I | 2011-02-17 |
20110039756 | MHC RAPID ASSAY USED FOR THE CUSTOMIZATION OF ODOURS - The present invention provides a user friendly test kit for determining an individual's Major Histocompatibilty profile and using that profile for the customization of odours. | 2011-02-17 |
20110039757 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the human bitter-taste receptor hTAS2R3 and its role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R3 bitter taste transduction or bitter taste response. | 2011-02-17 |
20110039758 | Molecular Interactions in Neurons - Inhibitors that disrupt binding between a PDZ protein and cognate ligands such as N-methyl-D-aspartate (NMDA) receptors that are involved in various neurological disorders are provided. Pharmaceutical compositions containing such inhibitors and their use in treating neurological diseases such as stroke and ischemia are also disclosed. Screening methods to identify additional inhibitors of specific protein ligand interactions with PDZ proteins are also described. | 2011-02-17 |
20110039759 | Use of Secretin-Receptor Ligands in Treatment of Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) - The invention is based on the finding that the secretin receptor is expressed in tissues present in the distal lung of humans. In patient with CF, levels of the receptor are elevated compared to the normal tissue. Treatment of tissue by secretin stimulates the movement of negative ions in the tissue. The invention provide method of treating cystic fibrosis or COPD in a patient by administering to said patient an effective amount of an agent which triggers anion efflux in respiratory tissue via the activation of the secretin receptor. | 2011-02-17 |
20110039760 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. | 2011-02-17 |
20110039761 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 2011-02-17 |
20110039762 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 2011-02-17 |
20110039763 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 2011-02-17 |
20110039764 | THERAPEUTIC COMPOSITION FOR BONE INFECTIOUS DISEASE - A biodegradable composition containing an antibiotic or a physiologically active substance for use in surgical treatment of infection. A highly safe and biocompatible composition showing appropriately sustained release of an antibiotic or physiologically active substance which produces excellent antibiotic and bone regenerating effects. A composition having excellent effects in treatment of bone infection occurring after operations for total arthroplasty and/or bone fracture. (1) A medical composition for treatment of bone infection comprising an antibiotic and a polysaccharide. | 2011-02-17 |
20110039765 | Bioactive Molecules Produced by Probiotic Bacteria - The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as | 2011-02-17 |
20110039766 | METHODS FOR PREVENTING OR TREATING METABOLIC SYNDROME - The invention provides methods of preventing or treating metabolic syndrome in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2011-02-17 |
20110039767 | FOOD COMPOSITIONS - The present inventors have found that collagen hydrolysate can be favorably used for the preparation of an edible composition for limiting voluntary food intake and hence are suitable for prevention and treatment of overweight and obesity. | 2011-02-17 |
20110039768 | FISH PROTEIN HYDROLYSATE HAVING A SATIETOGENIC ACTIVITY, NUTRACEUTICAL AND PHARMACOLOGICAL COMPOSITIONS COMPRISING SUCH A HYDROLYSATE AND METHOD FOR OBTAINING SAME, - The present invention relates to a fish protein hydrolysate containing molecules capable of exerting a satietogenic activity and of regulating food intake in humans or animals. More specifically, the protein hydrolysate according to the invention enables stimulation of the secretion of endogenous cholescystokinins (CCKs) and of endogenous glucagon-like peptide 1 (GLP1) molecules by intestinal cells and the supply of exogenous CCKs. The fish protein hydrolysate according to the invention is obtained by enzymatic hydrolysis of at least one protein source selected from the group composed of the pelagic fish species | 2011-02-17 |
20110039769 | INSULIN ALBUMIN CONJUGATES - Insulin albumin conjugates consisting of an insulin analogue, a bifunctional linker and albumin can efficiently be used to treat diabetic patients. | 2011-02-17 |
20110039770 | INHIBITORS OF PROTEIN KINASE C ISOFORMS AND USES THEREOF - Inhibitors of mammalian protein kinase C isoforms that comprise an inhibitor moiety, which is capable of inhibiting protein kinase activity, operatively associated with a peptide recognition element (PRE), which has an affinity for one or more PKC isoforms are provided. The targeted inhibitory molecules (TIMs) of the present invention are capable of inhibiting one or more PKC isoforms. The TIMs can be designed to target a specific PKC isoform by selection of a PRE component that is shown to preferentially target that PKC isoform. The TIMs are useful as therapeutic agents in the treatment of PKC-related diseases and disorders, such as cancer, psoriasis, angiogenesis, restenosis, atherosclerosis, cardiovascular disease, hypertension, diabetes, neurological disorders, rheumatoid arthritis, kidney disorders, inflammatory disorders and autoimmune disorders. | 2011-02-17 |
20110039771 | SMALL HUMANIN-LIKE PEPTIDES - Novel peptides referred to as small humanin-like peptides (SHLPs) are provided herein along with nucleic acids encoding SHLPs and probes that selectively bind SHLPs. SHLPs have wide-ranging activity, including neuroprotective activity, anticancer activity, and cell survival activity. Also provided herein are therapeutic methods comprising administering an effective amount of an SHLP to a subject in need of treatment. | 2011-02-17 |
20110039772 | NOVEL USES OF VEGFXXXB - The invention provides VEGF | 2011-02-17 |
20110039773 | BMP Mutants with Decreased Susceptibility to Noggin - The present invention provides modified, highly potent bone morphogenetic proteins. In particular, the present invention relates to the observation that BMP-6 and BMP-9 are less susceptible to inhibition by Noggin that are other members of the BMP subfamily of proteins. The present invention features chimeric bone morphogenetic proteins in which the middle portion of BMP-6 or BMP-9 replaces the middle portion of another BMP subfamily protein to cause resistance to inhibition by Noggin or other Noggin-like antagonists. Other embodiments of modified BMPs, compositions and methods of use are also included. | 2011-02-17 |
20110039774 | METHOD FOR REPAIRING NEURODEGENERATION - The present invention provides for treating neurodegeneration caused by nerve compression syndrome or entrapment neuropathy comprising administering human acidic fibroblast growth factor (aFGF), fibrinogen, aprotinin and divalent calcium ions to a subject in need thereof. | 2011-02-17 |
20110039775 | THYROID STIMULATING HORMONE FUSION PROTEINS - We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists. | 2011-02-17 |
20110039776 | FUSION PEPTIDE THERAPEUTIC COMPOSITIONS - Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life, etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs. | 2011-02-17 |
20110039777 | CANCER TREATMENT USING NATRIURETIC PEPTIDES - The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and/or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention. | 2011-02-17 |
20110039778 | Peptide Synthesis - A process for producing an insulin type peptide, for example a relaxin, involving oxidizing a methionine residue on a B-chain having cysteine residues and combining the B chain with an A chain having cysteine residues to form a peptide having intermolecular disulphide links and biological activity. Novel synthetic relaxin 1 and methionine oxidized relaxins and Met(O) B-chains having enhanced solubility are disclosed. | 2011-02-17 |
20110039779 | IGF-1R BINDING PROTEINS AND ANTAGONISTS - The present invention is drawn to new peptides and proteins that bind to human insulin-like growth factor-1 receptor (HIGF-IR), as well as nucleic acids encoding the same, vectors and cells comprising such nucleic acids, pharmaceutical compositions comprising such compounds, and methods of using any thereof, are provided. | 2011-02-17 |
20110039780 | PLATELET GLYCOPROTEIN IB ALPHA VARIANT FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides compositions and methods for treating or preventing vascular-associated disorders. | 2011-02-17 |
20110039781 | Treatment of Conditions Related to Cecal Ligation Shock - Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic. | 2011-02-17 |
20110039782 | SOYBEAN PROTEIN MATERIAL FOR PATIENTS WITH RENAL DISEASE AND FOODS MADE FROM THE SAME - Provided is a soybean protein material suitable for patients with renal disease which is highly effective in delaying the progression of renal disease, and foods for patients with renal disease made from the soybean protein material. The invention was completed upon obtaining knowledge that, among the acid-precipitable soybean proteins, fractionated soybean proteins obtained by increasing the purity of soy bean acid precipitable proteins other than 7S-globulin and 11S-globulin, specifically, “non-7S and 11S-acid-precipitable proteins,” have a strong effect in lowering albumin levels in urine. | 2011-02-17 |
20110039783 | PEPTIDE HAVING HYPOTENSIVE ACTIVITY - The present invention provides a novel peptide having a physiological activity. Because of having a hypotensive activity, this novel peptide is useful in treating a disease caused by hypertension. Also, an antibody to the novel peptide is provided. | 2011-02-17 |
20110039785 | POLYPEPTIDE-NUCLEIC ACID CONJUGATES AND USES THEREOF - The present invention is directed to polypeptide-nucleic acid conjugates. These conjugates can allow for targeted application of a therapeutic RNAi agent across the blood-brain barrier to treat, for example, a cancer, neurodegenerative disease, or lysosomal storage disorder. | 2011-02-17 |
20110039786 | METASTIN DERIVATIVE AND USE THEREOF - The present invention provides a metastin derivative represented by the formula (I): | 2011-02-17 |
20110039787 | COMPOSITIONS, KITS AND METHODS FOR TREATING BENIGN PROSTATE HYPERPLASIA - The present disclosure is directed to compositions and kits comprising degarelix or a pharmaceutically acceptable salt thereof for the treatment of benign prostate hyperplasia (BPH), methods for treating BPH, and methods for preparing compositions of degarelix or a pharmaceutically acceptable salt thereof. | 2011-02-17 |
20110039788 | COMPOSITIONS, METHODS AND KITS FOR DETECTING AND TREATING CANCER - Compositions, kits and methods for inhibiting cancer cell (e.g., breast cancer cell) growth and treating a subject with cancer (e.g., breast cancer) include a therapeutically effective amount of an LBH inhibitor for inhibiting cancer cell growth and a pharmaceutically acceptable carrier, and/or a therapeutically effective amount of Wnt7a protein or nucleic acids encoding Wnt7a protein for inhibiting cancer cell growth and a pharmaceutically acceptable carrier. Methods of treating a subject having cancer (e.g., estrogen receptor negative basal-type breast cancer) include administering to the subject a composition including a pharmaceutical carrier and at least one of: an LBH inhibitor, a WNT7a protein, and a nucleic acid encoding WNT7a protein in an amount effective for inhibiting growth of cancer cells in the subject. Methods of detecting the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in a subject include obtaining a biological sample from the subject; contacting the sample with at least one reagent that detects presence of LBH expression; measuring the level of LBH expression in the biological sample; and correlating overexpression of LBH with the presence of cancer (e.g., estrogen receptor negative basal-type breast cancer) in the subject. Kits for detecting the presence of basal-type breast cancer in a subject include at least one reagent for detecting the presence of LBH expression in a biological sample from the subject and instructions for use. | 2011-02-17 |
20110039789 | Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer - The present invention relates to new methods of treatment of cancer, in particular of breast cancer, and methods of screening of compounds useful in the treatment of cancer. The present invention further provides new prognostic and/or diagnostic markers in human cancer. | 2011-02-17 |
20110039790 | ENHANCED OCULAR NEUROPROTECTION AND NEUROSTIMULATION - Use of topically applied cyclosporine to enhance corneal sensitivity restoration rate in an eye of an individual after ocular surgery such as laser-assisted in situ keratomileusis (LASIK) in which nerves are severed. | 2011-02-17 |
20110039791 | ACETYLCHOLINESTERASE (ACHE)-DERIVED PEPTIDE AS AN INDUCER OF GRANULOCYTOPOIESIS, USES AND METHODS THEREOF - The present invention describes the use of an AChE-R-derived peptide, also known as ARP, as an inducer of hemopoietic cell differentiation and expansion, specifically for the granulocytic population. In addition, the use of ARP as an inducer of thrombopoietin and pro-inflammatory cytokines is also presented. ARP may further be used in the pre-transplant priming of hematopoietic stem cells. Other uses and methods utilizing ARP are also described herein. | 2011-02-17 |
20110039792 | Selective Targeting Agents for Mitochondria - The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels. In further preferred embodiments, the composition for scavenging radicals in a mitochondria membrane includes a radical scavenging agent and a membrane active compound having a high affinity with said mitochondrial membrane and associated methods. In another embodiment, the cargo transported by mitochondrial-selective targeting agents may include an inhibitor of nitric oxide synthase (NOS) enzyme activity. | 2011-02-17 |
20110039793 | Application of ginsenoside Rb1 in preparing medicaments for treating dilated cardiomyopathy - A method of preparing medicaments for treating dilated cardiomyopathy includes the step of applying ginsenoside Rb1. Long-term treatment of ginsenoside Rb1 can reduce the mortality rate, improve the cardiac function, reduce the dilation of the left ventricular, reduce the hypertrophy of myocytes and the proliferation of collagen, reduce the uneven thickness of myocytes, mitochondrial swelling, break of crista, sarcoplasmic reticulum expansion and destruction of intercalated disc connection, increase the expression of connexin Cx40, E-cadherin and P-cadherin, fibroblast growth factor FGF2, FGF7, FGF8, FGF10, and reduce the expression of integrin Itga8 and Itgbp. | 2011-02-17 |
20110039794 | Long Acting Injectable Formulations - Long acting injectable formulations of macrocyclic lactones comprising a biologically acceptable and biodegradable polyester polymer in a solvent system for use in the field of veterinary medicine, especially for use in combating ecto- and endoparasites in animals. | 2011-02-17 |
20110039795 | 2'-O,3'-N-BRIDGED MACROLIDES - Novel 2′-O,3′-N-bridged macrolides useful in treatment of inflammatory diseases. More particularly, the invention relates to 2′-O,3′-N-bridged 14-membered macrolides and to 2′-O,3′-N-bridged 15-membered azalide macrolides useful in treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to intermediates for their preparation, to the methods for their preparation, to their use as therapeutic agents, and to salts thereof. | 2011-02-17 |
20110039796 | Natural Composition for Anti-Angiogenesis and Anti-Obesity - The combination of gallic acid, ellagic acid, and rubusoside was shown to inhibit angiogenesis by inhibition of pro-angiogenic factors. These three compounds were shown to be absorbed from the intestine making the compounds orally bioavailable. The ratio of the three compounds in the composition was a weight ratio of approximately 1:1.7:17.0 of gallic acid, ellagic acid, and rubusoside, respectively, resulting in a composition with 5% w/w gallic acid, 9% w/w ellagic acid, and 86% w/w rubusoside. This combination was also shown to reduce weight gain, fat accumulation, and serum cholesterol in mammals fed a high fat diet. It also reduced serum triglycerides and tended to reduce blood glucose in mammals on both normal and high fat diets. This three-compound composition (“GER”) can be used to treat diseases associated with angiogenesis and to decrease effects of a high fat diet. | 2011-02-17 |
20110039797 | Oligomer Conjugates of Heteropentacyclic Nucleosides - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. | 2011-02-17 |
20110039798 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES - The present invention relates to fatty acid and fatty alcohol substituted nucleoside derivatives and nucleoside and nucleoside derivatives substituted on multivalent scaffolds (e.g., polymers, peptides, polycarboxylic acid substituted compounds, compounds containing polycycloSaligenyl groups) that display potent anti-HIV activity. Furthermore, they show enhanced activity against multi-drug resistant, R5, and cell-associated virus. Some of them also display activity against other sexually transmitted pathogens and sperm. The present invention provides their methods of synthesis, composition of matter, and methods of use. Emphasis is placed on their application as topical microbicides to treat or prevent sexual transmission of disease, especially HIV/AIDS. | 2011-02-17 |
20110039799 | A1 ADENOSINE RECEPTOR AGONIST POLYMORPHS - Provided are polymorphs of an A | 2011-02-17 |
20110039800 | PROLONGED RELEASE BIOADHESIVE THERAPEUTIC SYSTEMS - The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. Said bioadhesive therapeutic system comprises quantities of natural proteins representing at least 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar. | 2011-02-17 |
20110039801 | NK1 RECEPTOR ANTAGONIST COMPOSITION - An NK1 receptor antagonist composition of the present invention uses maltooligosaccharide having an NK1 receptor antagonistic activity as an active ingredient. A suitable amount of the maltooligosaccharide to be blended in the NK1 receptor antagonist composition of the present invention is 0.000001 to 70% by weight. The NK1 receptor antagonist composition of the present invention is prepared for use into various forms of external agents, internal medicines, foods and beverages by blending various materials as the ingredients other than the active ingredient. The NK1 receptor antagonist composition of the present invention has high safety for being used for pharmaceuticals and has satisfactory therapeutic effects. | 2011-02-17 |
20110039802 | NPY Y5 ANTAGONIST - The present invention provides a pharmaceutical composition for use as an NPY Y5 receptor antagonist comprising a compound of the formula (I): | 2011-02-17 |
20110039803 | SOLID FORMS OF AN ANTI-HIV PHOSPHOINDOLE COMPOUND - Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, provided herein are solid forms comprising (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(R)-phosphinic acid methyl ester, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, human immunodeficiency virus infection. | 2011-02-17 |
20110039804 | Composition of Risedronate and Vitamin D3 - The present invention is focused on compositions that contain risedronate and vitamin D as active ingredients. This dose combines the pharmaceutical properties of risedronate, which avoids bone degradation, and those from vitamin D, which fixates calcium to the bone, which are used for treating postmenopausal osteoporosis. | 2011-02-17 |
20110039805 | METHOD FOR TREATING MEIBOMIAN GLAND DISEASE - A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion. | 2011-02-17 |
20110039806 | COMBINED THERAPIES OF ANTIPSYCHOTIC DRUGS AND TETRACYCLINES IN THE TREATMENT OF PSYCHIATRIC DISORDERS - The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline. | 2011-02-17 |
20110039807 | ANTI-PARKINSONIAN COMPOUND ACETYLSALICYLIC ACID MALTOL ESTER - The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME). | 2011-02-17 |
20110039808 | Multitarget Compounds Active at a PPAR and Cannabinoid Receptor - There is a need for pharmaceutical compounds which have activity at, at least one of a PPAR and a cannabinoid receptor. Thus there are provided such compounds, wherein the compound comprises: a PPAR pharmacophore and a cannabinoid pharmacophore linked together by a moiety comprising a fused bicyclic ring comprising a five membered ring fused with a six membered ring or a six membered ring fused with a six membered ring; wherein the cannabinoid pharmacophore comprises the fused bicyclic ring; and the PPAR pharmacophore comprises a salicylic acid, alkoxybenzylacetic acid or a alkoxyphenylacetic acid functionality; and wherein the PPAR pharmacophore is linked to the bicyclic ring of the cannabinoid pharmacophore through a linker comprising an amine or an amide functional group. | 2011-02-17 |
20110039809 | COMBINED USE OF 25-HYDROXY-VITAMIN D3 AND VITAMIN D3 FOR IMPROVING BONE MINERAL DENSITY AND FOR TREATING OSTEOPORISIS - We disclose the combined use of vitamin D (cholecalciferol) and 25-OH D3 (calcifediol) to treat and/or prevent osteoporosis. One or more bisphosphonate compounds to inhibit bone resorption may also be used. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 2011-02-17 |
20110039810 | USE OF 25-HYDROXY-VITAMIN D3 TO AFFECT HUMAN MUSCLE PHYSIOLOGY - We disclose the use of 25-OH D3 (calcifediol) to increase muscle strength, muscle function, or both. Vitamin D3 (cholecalciferol) may optionally be used together with 25-OH D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 2011-02-17 |
20110039811 | TREATING HYPERGLYCEMIA WITH 25-HYDROXYVITAMIN D3 - We disclose treating hyperglycemia in a human with 25-hydroxyvitamin D3 (calcifediol). Blood glucose is reduced to a level which is closer to normal than baseline. Vitamin D3 (cholecalciferol) may optionally be used together with 25-hydroxy vitamin D3. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed. | 2011-02-17 |
20110039812 | N-ALKYLCARBONYL-D-AMINO HYDROXYALKYL ESTER COMPOUNDS AND THEIR USE - The present invention pertains to certain N-alkylcarbonyl-D-amino acid hydroxylalkyl esters (NACHE), including, for example, (R)-2-[((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-propionic acid 3-hydroxy-propyl ester, and compositions comprising such compounds, that target sensory elements on nerve fibers and which are usefully administered to refresh and cool the skin and mucous membranes. This disclosure generally relates to menthol-like cooling compounds, which do not have the smell, taste, or short duration of action of menthol. These compounds are designed for delivery onto the surfaces of the oral cavity, upper respiratory tract and skin. These compositions produce refreshing and cooling sensations and are expected to inhibit the perception of cough stimuli, itch, pain, and discomfort from the body's surfaces. In the oral cavity these compositions produce refreshing cooling without adverse effects on taste. These compounds have special utility for mouth refreshment and for the treatment of respiratory disorders such as cough, asthma, and chronic obstructive pulmonary diseases. In addition, topical use inhibits perception of itch, irritation, pain and discomfort. | 2011-02-17 |
20110039813 | METHOD OF UTILIZATION OF COMBINATION OF BENZOPHENONE DERIVATIVE OR SALT THEREOF AND IMMUNOSUPPRESSING AGENT, AND PHARMACEUTICAL COMPOSITION COMPRISING THESE COMPONENTS - Disclosed are use of a benzophenone derivative represented by general formula (I) or a salt thereof and one or more immunosuppressing agents in combination, and a pharmaceutical composition containing the benzophenone derivative or a salt thereof and one or more immunosuppressing agents. The use and the composition are useful for treatment or prevention of autoimmune diseases and the like. (In the formula, R | 2011-02-17 |
20110039814 | LIPID COMPOSITION - We describe lipid based pharmaceutical compositions adapted for oral delivery and optionally delivery in accordance with a circadian rhythm. | 2011-02-17 |
20110039815 | MACROCYCLIC METAL COMPLEXES FOR THEIR USE AS ANTICANCER AGENTS - In one embodiment the present invention relates to a method of treating cancerous cells in a mammal comprising the steps of administering to the cancerous cells an effective amount of a cyclic amine wherein the cyclic amine contains sulfur or nitrogen and the structure includes an interchealted metal ion. | 2011-02-17 |
20110039816 | THERAPEUTIC SUBSTANCE, PHARMACEUTICAL COMPOSITION, HELICOBACTER PYLORI GROWTH INHIBITOR AND METHOD FOR CONDUCTING ANTI-HELICOBACTER THERAPY - The invention belongs to the area of medicine and can be used as a therapeutic substance and as an inhibitor of the growth of | 2011-02-17 |
20110039817 | 4-AMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 RECEPTOR ANTAGONISTS - 4-Aminopyrimidine derivatives of formula (I) that are useful as histamine H4 receptor antagonists. | 2011-02-17 |
20110039818 | Dosage regimen of an S1P receptor agonist - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage. | 2011-02-17 |
20110039819 | SUBSTITUTED PHENOXYBENZAMIDES - The present invention relates to substituted phenoxybenzamide compounds of general formula (I): in which R | 2011-02-17 |
20110039820 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS - The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2011-02-17 |
20110039821 | Fused Phenyl Amido Heterocyclic Compounds - The present invention relates to a compound of formula (I): | 2011-02-17 |
20110039822 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS - The present invention provides a compound having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases, inflammatory diseases, and allergic diseases. | 2011-02-17 |
20110039823 | OXAZOLIDINONE ANTIBIOTICS - The invention relates to compounds of formula (I) wherein U, V, W, X, R1, R2, R3, R4, R5, R6, A, B, D, E, G, m, and n are as defined in the description, to pharmaceutically acceptable salts of such compounds for use in the manufacture of a medicament for the prevention or treatment of a bacterial infection. Certain compounds of formula (I) are new and are also part of this invention. | 2011-02-17 |
20110039824 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors - Provided are certain 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate compounds which are useful for modulating the activity of nuclear receptors, such as farnesoid X receptors, and/or for the treatment, prevention, or amelioration diseases or disorders related to the activity of these receptors. | 2011-02-17 |
20110039825 | LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE - The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT | 2011-02-17 |
20110039826 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS - This invention provides novel pharmaceutical compositions of the compound of formula (I): | 2011-02-17 |
20110039827 | Substituted hydroxamic acids and uses thereof - This invention provides compounds of formula (I): | 2011-02-17 |
20110039828 | TETRAHYDROQUINOLINE DERIVATIVES AND A PROCESS FOR PREPARING THE SAME - A novel compound of the formula (I): | 2011-02-17 |
20110039829 | PYRAZOLE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS - The present invention relates to compounds of the formula I, | 2011-02-17 |
20110039830 | CYCLIC INDOLE-3-CARBOXAMIDES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS - The present invention relates to cyclic indole-3-carboxamides of the formula I, | 2011-02-17 |
20110039831 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES - The invention relates to compounds of formula (I) and salts thereof | 2011-02-17 |
20110039832 | DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES - The invention relates to 5,6-dihydropyrrolo[2,1-a]isoquinoline and pyrrolo[2,1-a]isoquinoline derivatives according to general formula (I) or a pharmaceutically acceptable salt thereof. The compounds can be used for the treatment of infertility. | 2011-02-17 |
20110039833 | 1-BENZOYL SUBSTITUTED DIAZEPINE DERIVATIVES AS SELECTIVE HISTAMINE H3 RECEPTOR AGONISTS - The present invention relates to novel diazepanyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders. | 2011-02-17 |
20110039835 | SUBSTITUTED ARYLAMIDE DIAZEPINOPYRIMIDONE DERIVATIVES - The disclosure relates to a series pyrimidone derivatives represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof: | 2011-02-17 |